Viswanath Gunda - Concepedia

Author

Viswanath Gunda

Massachusetts General Hospital

Also Known As

G. Viswanath, Gunda Viswanath, V Gunda, V. Gunda, Viswanath G., Viswanath Gunda

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Massachusetts General Hospital Harvard University Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center Harvard University Press

About

Viswanath Gunda is an author at Massachusetts General Hospital specializing in medicine, cell biology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	839
2	Cell Biology	5	5	550
3	Biochemistry	2	2	338
4	Health Sciences	1	1	227
5	Public Health	1	1	33

Viswanath Gunda

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation Jiehui Deng, Eric S. Wang, Russell W. Jenkins, Cancer Discovery	2017	741
<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids Russell W. Jenkins, Amir Reza Aref, Patrick H. Lizotte, Cancer Discovery	2017	552
Transcription factor Nrf2 regulates SHP and lipogenic gene expression in hepatic lipid metabolism Jiansheng Huang, Iméne Tabbi‐Anneni, Viswanath Gunda, American Journal of Physiology-Gastrointestinal and Liver Physiology Nrf2 DeficiencyFatty Liver DiseaseOxidative StressMetabolic SyndromeTranscriptional Regulation	2010	227
Anti-androgenic endocrine disrupting activities of chlorpyrifos and piperophos Viswanath Gunda, Shamba Chatterjee, Swati Dabral, The Journal of Steroid Biochemistry and Molecular Biology Endocrine DisruptorsBiochemistryEndocrine MechanismMedicineToxicology	2010	111
Anti‐PD‐1/PD‐L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer Viswanath Gunda, Benjamin J. Gigliotti, Tameem Ashry, International Journal of Cancer Immune MicroenvironmentPmn‐mdsc ExpansionImmunologyImmunotherapeuticsImmunotherapy	2018	108
Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer Eran Brauner, Viswanath Gunda, Pierre Vanden Borre, Oncotarget ImmunologyImmunotherapyAnti Tumor ImmunityTumor BiologyTumor Immunology	2016	100
Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer Viswanath Gunda, Benjamin J. Gigliotti, Dorothy Ndishabandi, British Journal of Cancer	2018	100
Nuclear Receptor SHP, a Death Receptor That Targets Mitochondria, Induces Apoptosis and Inhibits Tumor Growth Yuxia Zhang, Jamie Soto, Kyungtae Park, Molecular and Cellular Biology MitophagyApoptosisCell DeathTumor BiologyOxidative Stress	2010	94
Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer Yanlan Liu, Viswanath Gunda, Xi Zhu, Proceedings of the National Academy of Sciences	2016	87
PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma Matthew W. Rosenbaum, Benjamin J. Gigliotti, Sara I. Pai, Endocrine Pathology Tumor BiologyThyroid DiseaseIdo1 ArePathologyMedicine	2018	72

Page 1